CapsoVision Submits FDA Application for AI-Enhanced Capsule Endoscopy System
核心洞察
CapsoVision (搜索) has submitted a 510(k) application to the FDA seeking clearance for its proprietary AI-assisted module for the CapsoCam Plus (搜索) small bowel capsule endoscope system.
The AI enhancement is designed to improve detection of clinically significant pathology and reduce clinician review time for small bowel diagnostics.
CapsoCam Plus (搜索) offers 360° panoramic imaging for patients aged 2 and older, with the original system receiving FDA clearance in 2016.
CapsoVision (搜索), Inc., a commercial-stage medical technology company, has submitted a 510(k) application to the FDA seeking clearance for its proprietary AI-assisted module designed for the CapsoCam Plus (搜索) capsule endoscopy system. The submission represents a significant advancement in small bowel diagnostic capabilities, integrating artificial intelligence with established imaging technology.
Enhanced Diagnostic Capabilities
The AI-assisted reading module is intended to improve the detection of clinically significant pathology and reduce clinician review time for small bowel examinations. The enhancement builds upon CapsoVision (搜索)'s flagship CapsoCam Plus (搜索) small bowel capsule endoscope system, which received FDA clearance in 2016.
CapsoCam Plus (搜索) is a third-generation capsule endoscopy system that provides a novel 360° view of the small bowel for detecting abnormalities. The system is indicated for small bowel visualization in patients aged 2 and older, offering advantages over other capsule endoscopy solutions through its imaging approach, clinical workflow, and patient experience.
Technology Integration
AI-enabled capsule endoscopy solutions integrate artificial intelligence and deep learning algorithms into the standard capsule endoscopy procedure. The vitamin-sized capsule contains a miniature wireless camera that captures thousands of images as it travels through the digestive tract.
CapsoVision (搜索)'s AI tools are developed internally and operate on a cloud-based platform that does not require on-site servers. This approach streamlines implementation and reduces infrastructure requirements for healthcare facilities.
Market Context and Commercial Outlook
According to Grand View Research, the global endoscopy devices market was estimated at $61.06 billion in 2024 and is projected to reach $76.55 billion by 2030, growing at a compound annual growth rate of 3.79% from 2025 to 2030.
U.S. commercialization of the AI-enhanced system is expected to begin following FDA clearance. Johnny Wang, President and Chief Executive Officer of CapsoVision (搜索), stated, "This submission marks an important milestone in our commitment to customers and patients towards advancing a best-in-class solution that integrates advanced imaging with AI-powered interpretation for small bowel diagnostics."
Financial Performance
For the nine months ended September 2025, CapsoVision (搜索) recorded net revenue of $9.64 million, representing an increase from $8.30 million in the same period the previous year. However, the company's net loss for the period widened to $17.92 million from a loss of $15.26 million a year ago.
The company's stock has traded between $3.43 and $15.37 over the past year, with shares closing at $11.58 following a 10.99% decline on the day of the announcement.